Abstract
Heme oxygenase-1 (HO-1) catalyzes the degradation of heme to generate carbon monoxide, biliverdin and free iron. Increased HO-1 levels constitute an anatomopathological feature of many neurological diseases, such as neurodegenerative disorders and brain infections, which correlate with exacerbated oxidative stress and inflammation. It is generally accepted that the elevated HO-1 levels represent an attempt to restore redox homeostasis and to down-modulate inflammation. However, experimental observations indicate that the extent of HO-1 induction may be critical because excessive heme degradation may result in toxic levels of CO, bilirubin and, more importantly, iron. Pharmacological modulation of HO-1 levels in the brain, within therapeutic limits, shows promising results in models of Alzheimers (AD), Parkinsons (PD) and of infectious diseases, such as malaria. A more complete understanding on how HO-1 is involved in the pathogenesis of neurological diseases will be essential to develop therapeutic approaches. In the next coming years we will witness the description of chemicals, drugs or dietary products that cross the blood brain barrier efficiently, activate HO-1 expression, and achieve neuroprotective and anti-inflammatory effects in vivo.
Keywords: Heme oxygenase-1, oxidative stress, neurodegenerative diseases, inflammation, microglia
Current Pharmaceutical Design
Title: Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections
Volume: 14 Issue: 5
Author(s): Antonio Cuadrado and Ana I. Rojo
Affiliation:
Keywords: Heme oxygenase-1, oxidative stress, neurodegenerative diseases, inflammation, microglia
Abstract: Heme oxygenase-1 (HO-1) catalyzes the degradation of heme to generate carbon monoxide, biliverdin and free iron. Increased HO-1 levels constitute an anatomopathological feature of many neurological diseases, such as neurodegenerative disorders and brain infections, which correlate with exacerbated oxidative stress and inflammation. It is generally accepted that the elevated HO-1 levels represent an attempt to restore redox homeostasis and to down-modulate inflammation. However, experimental observations indicate that the extent of HO-1 induction may be critical because excessive heme degradation may result in toxic levels of CO, bilirubin and, more importantly, iron. Pharmacological modulation of HO-1 levels in the brain, within therapeutic limits, shows promising results in models of Alzheimers (AD), Parkinsons (PD) and of infectious diseases, such as malaria. A more complete understanding on how HO-1 is involved in the pathogenesis of neurological diseases will be essential to develop therapeutic approaches. In the next coming years we will witness the description of chemicals, drugs or dietary products that cross the blood brain barrier efficiently, activate HO-1 expression, and achieve neuroprotective and anti-inflammatory effects in vivo.
Export Options
About this article
Cite this article as:
Cuadrado Antonio and Rojo I. Ana, Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections, Current Pharmaceutical Design 2008; 14 (5) . https://dx.doi.org/10.2174/138161208783597407
DOI https://dx.doi.org/10.2174/138161208783597407 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Retinal Degenerations: From Cell Signaling to Cell Therapy; Pre-Clinical and Clinical Issues
Current Gene Therapy Cellular Oxidative/Antioxidant Balance in γ-Irradiated Brain: An Update
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Neuropharmacology Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Body’s Energy Engine))
CNS & Neurological Disorders - Drug Targets Mapping Chemical Space Using Molecular Descriptors and Chemical Genetics: Deacetylase Inhibitors
Combinatorial Chemistry & High Throughput Screening Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Editorial [Hot topic: Inhibition and Function of Heat Shock Proteins 70 and 90 (Guest Editor: Brian S. J. Blagg)]
Current Topics in Medicinal Chemistry An Antioxidant Role by Minocycline Via Enhancing the Activation of LKB1/AMPK Signaling in the Process of Cerebral Ischemia Injury
Current Molecular Medicine Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Oxidative Imbalance and Anxiety Disorders
Current Neuropharmacology Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Hrd1 Facilitates Tau Degradation and Promotes Neuron Survival
Current Molecular Medicine Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry The Role of Calcium Stores in Apoptosis and Autophagy
Current Molecular Medicine Activity-dependent Synaptic Plasticity and Metaplasticity in Spinal Motor Networks
Current Pharmaceutical Design